Sarcoidosis is characterized by noncaseating granulomas which form in almost any part of
the body, primarily in the lungs and/or thoracic lymph nodes. Environmental exposures in …

Importance Sarcoidosis is an inflammatory granulomatous disease of unknown cause that
affects an estimated 2 to 160 people per 100 000 worldwide and can involve virtually any …

Background The major reasons to treat sarcoidosis are to lower the morbidity and mortality
risk or to improve quality of life (QoL). The indication for treatment varies depending on …

This British Thoracic Society (BTS) Clinical Statement addresses the diagnosis, evaluation
and management of pulmonary sarcoidosis, with each section summarised with key clinical …

Sarcoidosis is a systemic disease of unknown etiology defined by the presence of
noncaseating granulomatous inflammation that can cause organ damage and diminished …

Sarcoidosis is a systemic disease of unknown etiology characterized by the presence of
noncaseating granulomas in any organ, most commonly the lungs and intrathoracic lymph …

Multinational evidence-based World Association of Sarcoidosi... : Current Opinion in Pulmonary
Medicine Multinational evidence-based World Association of Sarcoidosis and Other …

A proportion of patients with interstitial lung diseases (ILDs) are at risk of developing a
progressive-fibrosing phenotype, which is associated with a deterioration in lung function …

About half of patients with sarcoidosis will need systemic therapy for their disease. Oral
glucocorticoids are the standard first-line treatment for sarcoidosis. With time, patients might …

Sarcoidosis is a multi-system disease of unknown etiology characterized by granuloma
formation in various organs (especially lung and mediastinohilar lymph nodes). In more than …